The transfusion service plays a critical role in the management of perinatal patients. This interactive session will engage the audience and speakers in an active discussion on approaches for testing and management of this patient population. Topics presented are those identified as controversial or for which there is no unified approach and include: • The timing and frequency of type and screens during pregnancy, and the need for type and screen with crossmatch at delivery. • The indications to perform molecular tests i.e., maternal RHD genotyping to distinguish weak D from partial D and fetal RHD genotyping using cell-free DNA to make decisions regarding the need for monitoring and Rh immune globulin administration. • Guidance about antibody critical titer thresholds and the appropriate management once critical titer is reached. • Suggestions regarding which cord blood tests should and should not be performed to diagnose and assess future risk of hemolytic disease of the fetus and newborn.
Director of Clinical Laboratories,
University of Vermont Medical Center